Having trouble accessing articles? Reset your cache.

Roche adds to fibrosis portfolio with $390M Promedior acquisition

Roche is adding a Phase III-ready idiopathic pulmonary fibrosis candidate to complement its IPF blockbuster Esbriet pirfenidone via the acquisition of Promedior for $390 million in upfront cash and up to $1 billion in milestones. The deal comes after Bristol-Myers passed on

Read the full 424 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE